Effects of 4-week treatment with low-dose budesonide (100 ?g BID) from a novel inhaler Airmax™ and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma
Effects of 4-week treatment with low-dose budesonide (100 ?g BID) from a novel inhaler Airmax™ and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma
This study investigated the effect of low dose of budesonide 100 ?g b.d from a new multi-dose dry powder inhaler (Airmax™) and from a conventional inhaler (Turbuhaler®) on bronchial hyper-responsiveness, lung function and asthma symptoms in mild stable asthmatics. Twenty-five patients were enrolled into a double-blind double-dummy crossover study with two 4-week treatment periods separated by a 4-week washout. Patients had a mean forced expiratory volume in 1 s (FEV?) of 91±13% predicted, had previously received inhaled short-acting ??-agonists only and had a PC?? to adenosine 5? monophosphate (AMP)<40 mg/ml. PC?? AMP was assessed at baseline, and at the start and end of each treatment period. Patients recorded peak expiratory flow and symptoms throughout the study. There was a mean increase in PC??AMP from start to end of 3.49 doubling dilutions (DD) in the Airmax™ group and 2.90 DD in the Turbuhaler® group. The difference was 0.60 DD(95% CI—0.47, 1.69) favouring Airmax™ and the upper limit exceeded the equivalence limit of ±1 DD. There were similar improvements in FEV?, daily PEF and symptoms in both groups. The majority of patients preferred treatment with Airmax™ to Turbuhaler® (64 vs. 23%). Both treatments were equally well tolerated. In conclusion, 100 ?g budesonide bid during 4 weeks from AirmaxTM effectively attenuates the response to AMP in mild asthmatics. Overall Airmax™ offers equal clinical benefit to Turbuhaler® and is preferred by patients.
dry powder inhaler, FEV?, adenosine 5?-monophosphate, airway hyper-reactivity, inflammation, clinical trial
542-547
Frew, A.J.
c00e9630-a5f0-44b3-add0-44b68836bbcb
Langley, S.J.
939fa822-cec0-44ed-8cca-f56d0c680a86
Perrin, V.
e880c25e-5223-4397-9b61-f6d950a28e1a
Hertog, M.G.L.
3f70a5cb-57f6-4a8d-944f-d9357d5ba604
2002
Frew, A.J.
c00e9630-a5f0-44b3-add0-44b68836bbcb
Langley, S.J.
939fa822-cec0-44ed-8cca-f56d0c680a86
Perrin, V.
e880c25e-5223-4397-9b61-f6d950a28e1a
Hertog, M.G.L.
3f70a5cb-57f6-4a8d-944f-d9357d5ba604
Frew, A.J., Langley, S.J., Perrin, V. and Hertog, M.G.L.
(2002)
Effects of 4-week treatment with low-dose budesonide (100 ?g BID) from a novel inhaler Airmax™ and from a conventional inhaler on bronchial hyper-responsiveness, lung function and symptoms in patients with mild asthma.
Respiratory Medicine, 96 (7), .
(doi:10.1053/rmed.2002.1290).
Abstract
This study investigated the effect of low dose of budesonide 100 ?g b.d from a new multi-dose dry powder inhaler (Airmax™) and from a conventional inhaler (Turbuhaler®) on bronchial hyper-responsiveness, lung function and asthma symptoms in mild stable asthmatics. Twenty-five patients were enrolled into a double-blind double-dummy crossover study with two 4-week treatment periods separated by a 4-week washout. Patients had a mean forced expiratory volume in 1 s (FEV?) of 91±13% predicted, had previously received inhaled short-acting ??-agonists only and had a PC?? to adenosine 5? monophosphate (AMP)<40 mg/ml. PC?? AMP was assessed at baseline, and at the start and end of each treatment period. Patients recorded peak expiratory flow and symptoms throughout the study. There was a mean increase in PC??AMP from start to end of 3.49 doubling dilutions (DD) in the Airmax™ group and 2.90 DD in the Turbuhaler® group. The difference was 0.60 DD(95% CI—0.47, 1.69) favouring Airmax™ and the upper limit exceeded the equivalence limit of ±1 DD. There were similar improvements in FEV?, daily PEF and symptoms in both groups. The majority of patients preferred treatment with Airmax™ to Turbuhaler® (64 vs. 23%). Both treatments were equally well tolerated. In conclusion, 100 ?g budesonide bid during 4 weeks from AirmaxTM effectively attenuates the response to AMP in mild asthmatics. Overall Airmax™ offers equal clinical benefit to Turbuhaler® and is preferred by patients.
This record has no associated files available for download.
More information
Published date: 2002
Keywords:
dry powder inhaler, FEV?, adenosine 5?-monophosphate, airway hyper-reactivity, inflammation, clinical trial
Identifiers
Local EPrints ID: 27051
URI: http://eprints.soton.ac.uk/id/eprint/27051
PURE UUID: 563ba646-367d-4cf9-a1e1-2c1da98205cc
Catalogue record
Date deposited: 26 Apr 2006
Last modified: 15 Mar 2024 07:15
Export record
Altmetrics
Contributors
Author:
A.J. Frew
Author:
S.J. Langley
Author:
V. Perrin
Author:
M.G.L. Hertog
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics